Clinical Trials in China / NCT05482269
Recruiting
Observational
Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
NCT05482269 · tracked via the Priya Life Science China tracker
Condition(s) studied
Pulmonary Embolism and ThrombosisDeterioration, ClinicalArtificial Intelligence
Investigational drug(s) / intervention(s)
no intervention
no intervention: no intervention
Study summary
The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.
Eligibility
Inclusion Criteria:
* age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography
Exclusion Criteria:
* pregnancy
* reception of reperfusion treatment before admission
* missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
Primary outcome measure(s)
- Incidence of Treatment-Emergent Adverse Events — 30 days
The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission. Adverse outcomes were defined as deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shengjing Hospital | Shenyang | Liaoning | Recruiting |
More Shengjing Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05482269 on ClinicalTrials.gov ↗ ← All trials in China